<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2805257479
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SIFROL 0.7MG (EQU. 1.00MG) TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PRAMIPEXOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        700
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        188.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BOEHRINGER INGELHEIM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N04BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SIFROL contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.</p><p>&nbsp;</p><p>SIFROL is used to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat the symptoms of primary Parkinson&rsquo;s disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson&rsquo;s disease).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take SIFROL:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to pramipexole or to any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor before taking SIFROL. Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney disease.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hallucinations (seeing, hearing or feeling things that are not there). Most hallucinations are visual.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs). If you have advanced Parkinson&rsquo;s disease and are also taking levodopa, you might develop dyskinesia during the up- titration of SIFROL.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)). In particular, you may experience forward flexion of the head and neck (also called antecollis), forward bending of the lower back (also called camptocormia) or sidewards bending of the back (also called pleurothotonus or Pisa Syndrome).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness and episodes of suddenly falling asleep.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychosis (e.g. comparable with symptoms of schizophrenia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision impairment. You should have regular eye examinations during treatment with SIFROL.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe heart or blood vessels disease. You will need to have your blood pressure checked regularly, especially at the beginning of treatment. This is to avoid postural hypotension (a fall in blood pressure on standing up).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Augmentation. You may experience that symptoms start earlier than usual, be more intense and involve other limbs.</p><p>&nbsp;</p><p>Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. <u>Your doctor may need to</u> <u>adjust or stop your dose.</u></p><p>&nbsp;</p><p>Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion or loss of reality). <u>Your doctor</u> <u>may need to adjust or stop your dose.</u></p><p>&nbsp;</p><p>Tell your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating or pain after stopping or reducing your SIFROL treatment. If the problems persist more than a few weeks, your doctor may need to adjust your treatment.</p><p>&nbsp;</p><p>Tell your doctor if you are developing an inability of keeping your body and neck straight and upright (axial dystonia). If this happens, your doctor may want to adjust or change your medication.</p><p>&nbsp;</p><p>Children and adolescents</p><p>SIFROL is not recommended for use in children or adolescents under 18 years.</p><p>&nbsp;</p><p>Other medicines and SIFROL</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines, herbal remedies, health foods or supplements that you have obtained without a prescription.</p><p>You should avoid taking SIFROL together with antipsychotic medicines. Take care if you are taking the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cimetidine (to treat excess stomach acid and stomach ulcers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amantadine (which can be used to treat Parkinson&rsquo;s disease)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisplatin (to treat various types of cancers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria))</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; procainamide (to treat irregular heart beat)</p><p>&nbsp;</p><p>If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with SIFROL.</p><p>&nbsp;</p><p>Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol. In these cases SIFROL may affect your ability to drive and operate machinery.</p><p>&nbsp;</p><p>SIFROL with food, drink and alcohol</p><p>You should be cautious while drinking alcohol during treatment with SIFROL. SIFROL can be taken with or without food.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will then discuss with you if you should continue to take SIFROL.</p><p>&nbsp;</p><p>The effect of SIFROL on the unborn child is not known. Therefore, do not take SIFROL if you are pregnant unless your doctor tells you to do so.</p><p>&nbsp;</p><p>SIFROL should not be used during breast-feeding. SIFROL can reduce the production of breast milk. Also, it can pass into the breast milk and can reach your baby. If use of SIFROL is unavoidable, breast-feeding should be stopped.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>SIFROL can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, do not drive or use machines.</p><p>&nbsp;</p><p>SIFROL has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson&rsquo;s disease. If you experience these side effects, you must not drive or operate machinery. You should tell your doctor if this occurs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The doctor will advise you on the right dosing.</p><p>&nbsp;</p><p>You can take SIFROL with or without food. Swallow the tablets with water.</p><p>&nbsp;</p><p>Parkinson&rsquo;s disease</p><p>The daily dose is to be taken divided into 3 equal doses.</p><p>&nbsp;</p><p>During the first week, the usual dose is 1 tablet SIFROL 0.088 mg three times a day (equivalent to</p><p>0.264 mg daily):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1<sup>st</sup> week</p></td></tr><tr><td style="vertical-align:top"><p>Number of tablets</p></td><td style="vertical-align:top"><p>1 tablet SIFROL 0.088 mg three times a day</p></td></tr><tr><td style="vertical-align:top"><p>Total daily dose (mg)</p></td><td style="vertical-align:top"><p>0.264</p></td></tr></tbody></table><p>&nbsp;</p><p>This will be increased every 5-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2<sup>nd</sup> week</p></td><td style="vertical-align:top"><p>3<sup>rd</sup> week</p></td></tr><tr><td style="vertical-align:top"><p>Number of tablets</p></td><td style="vertical-align:top"><p>1 tablet SIFROL 0.18 mg</p></td><td style="vertical-align:top"><p>1 tablet SIFROL 0.35 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>three times a day</p></td><td style="vertical-align:top"><p>three times a day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>OR</p></td><td style="vertical-align:top"><p>OR</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2 tablets SIFROL 0.088 mg</p></td><td style="vertical-align:top"><p>2 tablets SIFROL 0.18 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>three times a day</p></td><td style="vertical-align:top"><p>three times a day</p></td></tr><tr><td style="vertical-align:top"><p>Total daily dose (mg)</p></td><td style="vertical-align:top"><p>0.54</p></td><td style="vertical-align:top"><p>1.1</p></td></tr></tbody></table><p>&nbsp;</p><p>The usual maintenance dose is 1.1 mg per day. However, your dose may have to be increased even further. If necessary, your doctor may increase your tablet dose up to a maximum of 3.3 mg of pramipexole a day. A lower maintenance dose of three SIFROL 0.088 mg tablets a day is also possible.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lowest maintenance dose</p></td><td style="vertical-align:top"><p>Highest maintenance dose</p></td></tr><tr><td style="vertical-align:top"><p>Number of tablets</p></td><td style="vertical-align:top"><p>1 tablet SIFROL 0.088 mg three times a day</p></td><td style="vertical-align:top"><p>1 tablet SIFROL 0.7 mg</p><p>and 1 tablet SIFROL 0.35 mg three times a day</p></td></tr><tr><td style="vertical-align:top"><p>Total daily dose (mg)</p></td><td style="vertical-align:top"><p>0.264</p></td><td style="vertical-align:top"><p>3.15</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Patients with kidney disease</em></p><p>If you have moderate or severe kidney disease, your doctor will prescribe a lower dose. In this case, you will have to take the tablets only once or twice a day. If you have moderate kidney disease, the usual starting dose is 1 tablet SIFROL 0.088 mg twice a day. In severe kidney disease, the usual starting dose is just 1 tablet SIFROL 0.088 mg a day.</p><p>&nbsp;</p><p>Restless Legs Syndrome</p><p>The dose is usually taken once a day, in the evening, 2-3 hours before bedtime.</p><p>&nbsp;</p><p>During the first week, the usual dose is 1 tablet SIFROL 0.088 mg once a day (equivalent to 0.088 mg daily):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1<sup>st</sup> week</p></td></tr><tr><td style="vertical-align:top"><p>Number of tablets</p></td><td style="vertical-align:top"><p>1 tablet SIFROL 0.088 mg</p></td></tr><tr><td style="vertical-align:top"><p>Total daily dose (mg)</p></td><td style="vertical-align:top"><p>0.088</p></td></tr></tbody></table><p>&nbsp;</p><p>This will be increased every 4-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2<sup>nd</sup> week</p></td><td style="vertical-align:top"><p>3<sup>rd</sup> week</p></td><td style="vertical-align:top"><p>4<sup>th</sup> week</p></td></tr><tr><td style="vertical-align:top"><p>Number of tablets</p></td><td style="vertical-align:top"><p>1&nbsp; tablet SIFROL 0.18 mg OR</p><p>2&nbsp; tablets SIFROL</p><p>0.088 mg</p></td><td style="vertical-align:top"><p>1&nbsp; tablet SIFROL 0.35 mg OR</p><p>2&nbsp; tablets SIFROL 0.18 mg OR</p><p>4 tablets SIFROL</p><p>0.088 mg</p></td><td style="vertical-align:top"><p>1 tablet SIFROL 0.35 mg and 1 tablet SIFROL</p><p>0.18 mg OR</p><p>3 tablets SIFROL 0.18 mg OR</p><p>6 tablets SIFROL 0.088 mg</p></td></tr><tr><td style="vertical-align:top"><p>Total daily dose (mg)</p></td><td style="vertical-align:top"><p>0.18</p></td><td style="vertical-align:top"><p>0.35</p></td><td style="vertical-align:top"><p>0.54</p></td></tr></tbody></table><p>&nbsp;</p><p>The daily dose should not exceed 6 tablets SIFROL 0.088 mg or a dose of 0.54 mg (0.75 mg pramipexole salt).</p><p>&nbsp;</p><p>If you stop taking your tablets for more than a few days and want to restart the treatment, you must start again at the lowest dose. You can then build up the dose again, as you did the first time. Ask your doctor for advice.</p><p>&nbsp;</p><p>Your doctor will review your treatment after 3 months to decide whether or not to continue the treatment.</p><p>&nbsp;</p><p><em>Patients with kidney disease</em></p><p>If you have severe kidney disease, SIFROL may not be a suitable treatment for you.</p><p>&nbsp;</p><p>If you take more SIFROL than you should</p><p>If you accidentally take too many tablets,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact your doctor or nearest hospital casualty department immediately for advice.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may experience vomiting, restlessness, or any of the side effects as described in section 4 &ldquo;Possible side effects&rdquo;.</p><p>&nbsp;</p><p>If you forget to take SIFROL</p><p>Do not worry. Simply leave out that dose completely and then take your next dose at the right time. Do not try to make up for the missed dose.</p><p>&nbsp;</p><p>If you stop taking SIFROL</p><p>Do not stop taking SIFROL without first talking to your doctor. If you have to stop taking this medicine, your doctor will reduce the dose gradually. This reduces the risk of worsening symptoms.</p><p>&nbsp;</p><p>If you suffer from Parkinson&rsquo;s disease you should not stop treatment with SIFROL abruptly. A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk. The symptoms include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; akinesia (loss of muscle movement)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rigid muscles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unstable blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tachycardia (increased heart rate)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depressed level of consciousness (e.g. coma)</p><p>&nbsp;</p><p>If you stop or reduce SIFROL you may also develop a medical condition called dopamine agonist withdrawal syndrome. The symptoms include depression, apathy, anxiety, fatigue, sweating or pain. If you experience these symptoms you should contact your physician.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Evaluation of these side effects is based on the following frequencies:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>may affect more than 1 in 10 people</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>may affect up to 1 in 10 people</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>may affect up to 1 in 100 people</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>may affect up to 1 in 1,000 people</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>may affect up to 1 in 10,000 people</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Frequency cannot be estimated from the available data</p></td></tr></tbody></table><p>&nbsp;</p><p><em>If you suffer from Parkinson&rsquo;s disease, you may experience the following side effects:</em></p><p><em>&nbsp;</em></p><p>Very common:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (sickness)</p><p>&nbsp;</p><p>Common:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urge to behave in an unusual way</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hallucinations (seeing, hearing or feeling things that are not there)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness (fatigue)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleeplessness (insomnia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excess of fluid, usually in the legs (peripheral oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension (low blood pressure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal dreams</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual impairment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (being sick)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss including decreased appetite</p><p>&nbsp;</p><p>Uncommon:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paranoia (e.g. excessive fear for one&rsquo;s own well-being)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive daytime sleepiness and suddenly falling asleep</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amnesia (memory disturbance)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperkinesia (increased movements and inability to keep still)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (e.g. rash, itching, hypersensitivity)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inappropriate antidiuretic hormone secretion*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea (difficulties to breathe)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hiccups</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia (infection of the lungs)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strong impulse to gamble excessively despite serious personal or family consequences.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncontrollable excessive shopping or spending</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delirium (decreased awareness, confusion, loss of reality)</p><p>&nbsp;</p><p>Rare:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mania (agitation, feeling elated or over-excited)</p><p>&nbsp;</p><p>Not known:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After stopping or reducing your SIFROL treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).</p><p>&nbsp;</p><p>Tell your doctor if you experience any of these behaviours; he will discuss ways of managing or reducing the symptoms.</p><p><strong>&nbsp;</strong></p><p>For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 2,762 patients treated with pramipexole. The frequency category is probably not greater than &ldquo;uncommon&rdquo;.</p><p>&nbsp;</p><p><em>If you suffer from Restless Legs Syndrome, you may experience the following side effects:</em></p><p><em>&nbsp;</em></p><p>Very common:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (sickness)</p><p>&nbsp;</p><p>Common:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in sleep pattern, such as sleeplessness (insomnia) and sleepiness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness (fatigue)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal dreams</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (being sick)</p><p>&nbsp;</p><p>Uncommon:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urge to behave in an unusual way*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inappropriate antidiuretic hormone secretion*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperkinesia (increased movements and inability to keep still)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paranoia (e.g. excessive fear for one&rsquo;s own well-being)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delusion*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amnesia (memory disturbance)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hallucinations (seeing, hearing or feeling things that are not there)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive daytime sleepiness and suddenly falling asleep</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension (low blood pressure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excess of fluid, usually in the legs (peripheral oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (e.g. rash, itching, hypersensitivity)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual impairment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss including decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea (difficulties to breathe)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hiccups</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia (infection of the lungs)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strong impulse to gamble excessively despite serious personal or family consequences.*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncontrollable excessive shopping or spending*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mania (agitation, feeling elated or over-excited)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delirium (decreased awareness, confusion, loss of reality)*</p><p>&nbsp;</p><p>Not known:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After stopping or reducing your SIFROL treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).</p><p>&nbsp;</p><p>Tell your doctor if you experience any of these behaviors; he will discuss ways of managing or reducing the symptoms.</p><p><strong>&nbsp;</strong></p><p>For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 1,395 patients treated with pramipexole. The frequency category is probably not greater than &ldquo;uncommon&rdquo;.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>Store in the original package to protect the tablets from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pramipexole.</p><p>&nbsp;</p><p>Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg pramipexole as 0.125 mg, 0.25 mg,</p><p>0.5 mg, or 1 mg pramipexole dihydrochloride monohydrate, respectively.</p><p>&nbsp;</p><p>The other ingredients are mannitol, maize starch, anhydrous colloidal silica, povidone K 25 and magnesium stearate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                SIFROL 0.088 mg tablets are white, of round shape, flat, and without scoring.

SIFROL 0.18 mg tablets and SIFROL 0.35 mg tablets are white, of oval shape, and flat. Tablets are scored on both sides and breakable in halves.

SIFROL 0.7 mg tablets are white, of round shape, and flat. Tablets are scored on both sides and breakable in halves.

All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P6, P7, P8, or P9 on the other side, representing the tablet strengths 0.088 mg, 0.18 mg, 0.35 mg, and
0.7 mg, respectively.

All strengths of SIFROL are available in aluminium blister strips of 10 tablets per strip, in cartons containing 3 or 10 blister strips (30 or 100 tablets). Not all pack sizes or strengths may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Boehringer Ingelheim International GmbH D-55216 Ingelheim am Rhein</p><p>Germany</p><p>&nbsp;</p><p>Manufacturer</p><p><strong>&nbsp;</strong></p><p>Boehringer Ingelheim Pharma GmbH &amp; Co. KG D-55216 Ingelheim am Rhein</p><p>Germany</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Kingdom of Saudi Arabia (Scientific Office)</p><p>Riyadh.</p><p>Tel: +966-11-5116504</p><p>Fax: +966-11-5116545</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Feb 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي عقار سيفرول إالى مجموعة أدوية تسمى ناهضات الدوبامين ،وهي تحفز مستقبلات الدوبامين في المخ .ويودي تحفيز مستقبلات الدوبامين إلى توليد الإشارات العصبية في المخ مما يساعد على التحكم&nbsp; في حركات الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يستخدم عقار سيفرول :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج أعراض مرض الشلل الرعاشي (مرض باركينسون) الأساسي، ويمكن استخدام هذا العقار بمفرده أو بمصاحبة عقار ليفودوبا (دواء اخر يستخدم لعلاج مرض الشلل الرعاشي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج أعراض متلازمة تململ الساقين الأولية المتوسطة إلى الشديدة لدى البالغين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول عقار سيفرول</p><p dir="RTL">إذا كنت تعاني من حساسية (فرط الحساسية) تجاة براميبكسول أو أي من المكونات الأخرى بالأقراص (انظر القسم 6،معلومات إضافية ).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحذيرات و احتياطات</p><p dir="RTL">أخبر طبيبك إذا كنت تعاني (أو قد عانيت مسبقا) أو تعرضت لأي حالات طبية أو أعراض ،ولا سيما أي ممايلي:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض بالكلى</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلاوس (رؤية أو سماع الشعور بأشياء غير موجودة). تكون معظم الهلاوس بصرية .</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الحركة (على سبيل المثال حركات الأطراف غير الطبيعية والتي لأ يمكن التحكم فيها). إذا كنت تعاني من حالة متقدمة من مرض شلل الرعاش ،وكنت تتناول أيضا عقار ليفودوبا ،فقد تعاني من خلل الحركة خلال زيادة جرعة عقار سيفرول تدريجيا (المعايرة التصاعدية).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل التوتر (عدم القدرة على إبقاء الجسم والرقبة في وضعية مستقيمة ومنتصبة [خلل التوتر المحوري]). على وجه الخصوص، قد تتعرَّض لانحناء بالرأس والرقبة إلى الأمام (ما يُسمى أيضًا بالصعر الأمامي)، أو انحناء الجزء السفلي من الظهر إلى الأمام (ما يُسمى أيضًا بانعطاف الجذع التشنجي) أو انحناء الظهر إلى أي من الجانبين (ما يُسمى أيضًا بالتقوس الجانبي أو متلازمة بيزا).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس ونوبات نوم مفاجئة.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذهان (مقارنة بأعراض الفصام على سبيل المثال).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف البصر، يجب عليك إجراء فحوصات منتظمة للعينين خلال العلاج بعقار سيفرول .</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض شديد بالقلب أو الأوعية الدموية،سيتوجب فحص ضغط الدم لديك بانتظام، خاصة في بداية العلاج، وذلك من أجل تفادي حدوث انخفاض ضغط الدم الانتصابي (وهو انخفاض في ضغط الدم يحدث عند الوقوف(.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم مرض الشلل الرعاشي. من الممكن أن تعاني من أعراض تفاقم هذا المرض والتي قد تظهر مبكرا عن المعتاد (عن ماهو متوقع)،وقد تكون أكثر شدة وقد تصيب أطرافا أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا لا حظت أنت أو عائلتك / مقدم الرعاية أنك تقوم بتطوير التحفيز أو الرغبة الشديدة في التصرف بطريقة غير اعتيادية بالنسبة لك ولا يمكنك مقاومة الدافع أو القيادة أو إغراء تنفيذ بعض الانشطة التي قد تضر نفسك أو الآخرين.</p><p dir="RTL">وتسمى هذه الاضطربات السيطرة على الاندفاع ويمكن أن تشمل السلوكيات مثل القمار، الإدمان، الإفراط في تناول الطعام أو الإنفاق،و الإندفاع الجنسي العالي بشكل غير طبيعي أو الانشغال مع زيادة في الأفكار الجنسية أو المشاعر. قد يحتاج طبيبك إلى تعديل الجرعة أو إيقافها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا لاحظت أنت أو عائلتك / مقدم الرعاية أنك مصاب بحالة من الهوس (هياج، شعور بالابتهاج أو فرط الاستثارة) أو هذيان (انخفاض الوعي أو الارتباط أو فقدان الصلة بالواقع). قد يحتاج طبيبك إلى تعديل أو يقاف الجرعة الخاصة بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا واجهت أعرضا مثل: الاكتئاب أو الإرهاق أو الألم بعد التوقف عن العلاج بعقار سيفرول أو خفض الجرعة. إذا استمرت المشاكل لأكثر من بضعة أسابيع، فقد يحتاج طبيبك إلى تعديل علاجك.</p><p dir="RTL">أخبر طبيبك إذا أصبت بعدم القدرة على إبقاء الجسم والرقبة في وضعية مستقيمة ومنتصبة (خلل التوتر المحوري). إذا حدث ذلك، فقد يرغب طبيبك في تعديل علاجك أو تغييره.</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">لايوصى باستعمال عقار سيفرول للأطفال أو المراهقين ممن تقل أعمارهم عن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول أدوية أخرى</p><p dir="RTL">يرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو قد تناولت مؤخرا أدوية أخرى، بما في ذلك الأدوية أو العلاجات العشبية أو الأطعمة الصحية أو المكملات الغذائية التي حصلت عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تتناول عقار سيفرول مع الأدوية النفسية (المضادة للذهان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">توخ الحذر إذاكنت تتناول أي دواء من الأدوية التالية:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيميتيدين (وهو دواء يستخدم لعلاج حمض المعدة الزائد وقرحات المعدة).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار أمانتادين (وهو دواء يمكن استخدامه لعلاج مرض الشلل الرعاش).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار ميكسيلتين (وهو دواء يستخدم لعلاج عدم انتظام ضربات القلب،وهي حالة تعرف باسم اضطراب النظم البطيني).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار زيدوفيودين (وهو دواء يستخدم لعلاج عدم انتظام ضربات القلب،وهي حالة تعرف باسم اضطراب النظم البطيني).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيسبلاتين (وهو دواء يستخدم لعلاج أنواع مختلفة من السرطان).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار كينين (وهو دواء يمكن استخدامة لمنع حدوث تقلصات مؤلمة بالساق أثناء الليل ولعلاج نوع من أنواع الملاريا يعرف باسم ملاريا المتصورات المنجلية __الملاريا الخبيثة).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار بروكايناميد (وهو دواء لعلاج عدم انتظام ضربات القلب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول عقار ليفودوبا،فيوصى بخفض جرعة عقار ليفودوبا عند بدء العلاج بعقار سيفرول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توخ الحذر إذا كنت تستخدم أية أدوية لتهدئتك (لها أثر مهدئ)أو إذا كنت تتناول الكحوليات. حيث قد يؤثر عقار سيفرول في هذه الحالات في قدرتك على ممارسة القيادة وتشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول عقار سيفرول مع الأطعمة والمشروبات</p><p dir="RTL">يجب أن تكون حذرا أثناء تناؤل الكحوليات خلال فترة العلاج بعقار سيفرول. يمكن تناول عقار سيفرول مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل والرضاعة الطبيعية</p><p dir="RTL">أخبري طبيبك إذا كنت حاملا أو إذ كنت تنوين الحمل. سيناقشك طبيبك حينئذ حول ما إذا كان ينبغي عليك الاستمرار في تناول عقار سيفرول أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعد أثر عقار سيفرول على الجنين غير معروف؛ ولذلك لا تتناولي عقار سيفرول إذا كنت حاملا مالم يخبرك طبيبك بتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لايجب استخدام عقار سيفرول أثناء الرضاعة الطبيعية. قد يقلل عقار سيفرول من إنتاج لبن الأم، كما قد يمر في لبن الأم، ويصل إلى الطفل. إذا كان استخدام عقار سيفرول أمرا حتميا، فيجب حينئذ إيقاف الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري الطبيب أو الصيدلي الخاص بك قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">قد يسبب عقار سيفرول هلاوس (رؤية أو سماع أو الشعور بأشياء غير موجودة). إذا تأثرت بهذه الهلاوس، فلا تمارس القيادة ولا تستخدم أية آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصاحب استخدام عقار سيفرول حدوث نعاس ونوبات نوم مفاجئ، خاصة لدى المرضى المصابين بمرض الشلل الرعاشي. إذا كنت تعاني من هذه الاثار، فلا يجب أن تمارس القيادة أو تقوم&nbsp; بتشغيل&nbsp; آلات، ويجب عليك أن تخبر طبيبك إذا ما حدث ذلك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائما بتناول عقار سيفرول كما أخبرك طبيبك بالضبط. سيخبرك طبيبك بالجرعة المناسبة.</p><p dir="RTL">يمكن تناول عقار سيفرول مع الطعام أو بدونه. ابتلع الأقراص كاملة مع الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مرض شلل الرعاش</strong></p><p dir="RTL">يجب تناول الجرعة اليومية مقسمة على 3 جرعات متساوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">خلال الاسبوع الأول، تكون الجرعة المعتادة قرص واحد من عقار سيفرول 0.088 مجم ثلاث مرات في اليوم (بما يعادل 0.264 مجم يوميا)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الاسبوع الأول</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدد الأقراص</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.088 مجم ثلاث مرات في اليوم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إجمالي الجرعة اليومية (مجم)</p></td><td style="vertical-align:top"><p dir="RTL">0.264</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">ثم تتم زيادة هذه الجرعة كل 5-7 أيام وفقا لأرشادات طبيبك حتى تتم السيطرة على الأعراض (جرعة المداومة).</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:559px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الاسبوع الثاني</p></td><td style="vertical-align:top"><p dir="RTL">الاسبوع الثالث</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدد الأقراص</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.18 مجم ثلاث مرات في اليوم أو قرصان من عقار سيفرول0.088 مجم ثلاث مرات في اليوم</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.35 مجم ثلاث مرات في اليوم أو قرصان من عقار سيفرول 0.18 مجم ثلاث مرات في اليوم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إجمالي الجرعة اليومية(مجم)</p></td><td style="vertical-align:top"><p dir="RTL">0.54</p></td><td style="vertical-align:top"><p dir="RTL">1.1</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة المداومة المعتادة هي 1.1 مجم في اليوم. ومع ذلك، قد تتم زيادة جرعتك لأكثر من ذلك. إذا لزم الأمر ، قد يزيد طبيبك جرعة الأقراص الخاصة بك لتصل إلى 3.3 مجم كحد أقصلا من براميبكسول في اليوم. كما يمكن وصف جرعة مداومة أقل في هيئة ثلاث أقراص من عقار سيفرول 0.088 مجم في اليوم.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقل جرعة مداومة</p></td><td style="vertical-align:top"><p dir="RTL">أعلى جرعة مداومة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدد الأقراص</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.088 مجم ثلاث مرات في اليوم</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.7 مجم و قرص واحد من عقار سيفرول 0.35 مجم &nbsp;ثلاث مرات في اليوم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إجمالي الجرعة اليومية(مجم)</p></td><td style="vertical-align:top"><p dir="RTL">0.264</p></td><td style="vertical-align:top"><p dir="RTL">3.15</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>المرضى الذين يعانون من مرض بالكلى </em></strong></p><p dir="RTL">إذا كنت تعاني من مرض متوسط أو شديد بالكلى، فقد يصف لك طبيبك جرعة أقل. في هذه الحالة، سيتوجب عليك تناول الأقراص مرة أو مرتين في اليوم. إذا كنت تعاني من مرض شديد بالكلى، تكون جرعة البدء المعتادة قرص واحد من عقار سيفرول 0.088 مجم مرتين في اليوم. أما إذا كنت تعاني من مرض شديد بالكلى، تكون جرعة البدء المعتادة قرص واحد فقط من عقار سيفرول 0.088 مجم في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متلازمة تململ الساقين</strong></p><p dir="RTL">عادة مايتم تناول الجرعة مرة واحدة في اليوم، في المساء، قبل موعد النوم بساعتين إلى 3 ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">خلال الاسبوع الأول، تكون الجرعة المعتادة قرص واحد من عقار سيفرول 0.088 مجم مرة واحدة في اليوم (بما يعادل 0.088 مجم يوميا): ثم تتم زيادة هذه الجرعة كل 4-7 أيام وفقا لإرشادات طبيبك حتى تتم السيطرة على الأعرض (جرعة المداومة).</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الاسبوع الأول</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدد الأقراص</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول0.088 مجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إجمالي الجرعة اليومية (مجم)</p></td><td style="vertical-align:top"><p dir="RTL">0.088</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الاسبوع الثاني</p></td><td style="vertical-align:top"><p dir="RTL">الاسبوع الثالث</p></td><td style="vertical-align:top"><p dir="RTL">الاسبوع الرابع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدد الأقرص</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.18 مجم أو قرصان من عقار سيفرول 0.088 مجم</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.35 مجم أو قرصان من عقار سيفرول 0.18 مجم أو 4 أقراص من عقار سيفرول 0.088 مجم</p></td><td style="vertical-align:top"><p dir="RTL">قرص واحد من عقار سيفرول 0.35 مجم وقرص واحد من عقار سيفرول 0.18 مجم أو 3أقراص من عقار سيفرول 0.18 مجم أو 6 أقراص من عقار سيفرول 0.088 مجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إجمالي الجرعة اليومية (مجم)</p></td><td style="vertical-align:top"><p dir="RTL">0.18</p></td><td style="vertical-align:top"><p dir="RTL">0.35</p></td><td style="vertical-align:top"><p dir="RTL">0.54</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تتجاوز الجرعة اليومية 6 أقراص من عقار سيفرول 0.088 مجم أو جرعة بحجم 0.54 مجم (0.75 مجم ملح براميسكسول(.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت عن تناول أقراصك لأكثر من بضعة&nbsp; أيام ثم أردت عادة بدء العلاج، فيجب أن تبدا مجددا بأقل جرعة. ثم يمكنك بعد ذلك زيادة الجرعة بشكل تدريجي مرة أخرى، تماما مثلما فعلت في أول مرة. استشر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بتقييم علاجك بعد مرور 3اشهر ليقرر استمرارك في العلاج من عدمه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>المرضى الذين يعانون من مرض بالكلى</em></strong></p><p dir="RTL">إذا كنت تعاني من مرض شديد بالكلى، فقد يكون العلاج بعقار سيفرول غير مناسبا لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية من عقار سيفرول أكثر مما يجب </strong></p><p dir="RTL">إذا تناولت أقراصا كثيرة جدا بطريق الخطأ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاتصل بطبيبك أو بقسم الطوارئ بأقرب مستشفى على الفور للحصول على المشورة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تعاني من قيء، أو شعور بعدم راحة، أو أي من الآثار الجانبية الموضحة في القسم 4 &quot;الآثار الجانبية المحتملة&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناول عقار سيفرول</strong></p><p dir="RTL">لا داعي للقلق. تجاهل ببساطة هذه الجرعة تماما ثم تناول جرعتك التالية في الوقت المحدد. لا تحاول تعويض الجرعة التي اغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول عقار سيفرول </strong></p><p dir="RTL">لا تتوقف عن تناول عقار سيفرول بدون استشارة طبيبك أولاً. إذا كان يجب التوقف عن تناول هذا الدواء،فسيقوم طبيبك بخفض الجرعة تدريجيا. سيقلل ذلك من خطر تدهور الأعرض .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من مرض الشلل الرعاشي فلا يجب أن توقف العلاج بعقار سيفرول بشكل مفاجئ. حيث قد يؤدي الإيقاف المفاجئ إلى حدوث حالة طبية قد تمثل خطر كبيرا على صحتك. وتتضمن الاعراض مايلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعذر الحركة (فقدان القدرة على تحريك العضلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم غير مستقر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الوعي (على سبيل المثال: غيبوبة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت أو قللت من استخدام عقار سيفرول ، فقد تصاب بحالة طبية تسمى متلازمة انسحاب ناهض الدوبامين. تشمل الأعراض الاكتئاب واللامبالاة والقلق والتعب والتعرق أو الألم. إذا واجهت هذه الأعراض ، يجب عليك الاتصال بطبيبك.</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى حول استخدام هذا المنتج، فاسأل الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من حدوثها لدى الجميع. يعتمد تقييم الآثار الجانبية على معدلات التكرار التالية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">شائعة جدا</p></td><td style="vertical-align:top"><p dir="RTL">قد تؤثر على أكثر من شخص واحد من بين كل 10 أشخاص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شاعة</p></td><td style="vertical-align:top"><p dir="RTL">قد تؤثر على مايصل إلى شخص واحد من بين كل 10 أشخاص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غير شائعة</p></td><td style="vertical-align:top"><p dir="RTL">قد تؤثر على مايصل إلى شخص واحد من بين كل 100 شخص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نادرة</p></td><td style="vertical-align:top"><p dir="RTL">قد يؤثر على مايصل إلى شخص واحد من بين كل 1000 شخص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غير نادرة جدا</p></td><td style="vertical-align:top"><p dir="RTL">قد يؤثر على مايصل إلى شخص واحد من بين كل 10000 شخص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غير معروفة</p></td><td style="vertical-align:top"><p dir="RTL">لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من مرض الشلل الرعاشي (مرض باركنسون)، فقد تتعرض للآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدا:</strong></p><p dir="RTL">- خلل الحركة (على سبيل المثال: حركات غير طبيعية وغير منضبطة للأطراف).</p><p dir="RTL">- نعاس.</p><p dir="RTL">- دوخة.</p><p dir="RTL">- غثيان (إعياء)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة ملحة للتصرف بطريقة غير معتادة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلاوس (رؤية أو سماع أو الشعور بأشياء لا وجود لها).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك/التباس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب (إرهاق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (أرق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السوائل، عادة في الساقين (وذمة طرفية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلام غير طبيعية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور البصر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء (إعياء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن بما في ذلك فقدان الشهية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جنون الارتياب (على سبيل المثال:خوف مبالغ فية على الصحة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوهام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس مفرط أثناء النهار والنوم فجأة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة (اضطراب بالذاكرة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحراك (زيادة الحركة والعجز عن البقاء ساكنا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (على سبيل المثال: طفح جلدي، حكة، فرط الحساسية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب (مشاكل بالقلب قد تسبب ضيقا بالتنفس أو تورم الكاحل)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفراز غير مناسب للهرمون المضاد لإدرار البول*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تململ (الشعور بعدم ارتياح).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس (صعوبان في التنفس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فواق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي (عدوى بالرئتين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز عن مقاومة الرغبة الدافع أو الإغراء لفعل ماقد يضرك أو يضر الآخرين ، والذي قد يتضمن:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة قوية للعب القمار بشكل مفرط بالرغم من أن له عواقب شخصية أو عائلية خطير.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير أو زيادة الرغبة الجنسية والسلوك الذي يثير قلقا كبيرا لك أو للأخرين، مثل: زيادة الدافع الجنسي.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بالتسوق أو الإنفاق المفرط غير المتحكم به.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شراهة (تناول كميات كبيرة من الطعام خلال مدة قصيرة) أو نهم (تناول كمية من الطعام أكبر من المعدل الطبيعي وأكثر من المطلوب لإ شباع جوعك)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهذيان (انخفاض الوعي، ارتباكا/ التباسا، فقدان الصلة بالواقع).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هوس (هياج، شعور بالابتهاج أو فرط الاستثارة).</p><p dir="RTL"><strong>غير معروفة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد التوقف عن العلاج بعقار سيفرول أو خفض الجرعة: قد يحدث اكتئاب أو لا مبالاة أو قلق أو ارهاق أو تعرق أو ألم (تسمى بمتلازمة انسحاب ناهض الدوبامين).</p><p dir="RTL"><strong>أخبر طبيبك إذا كنت تواجه أيا من هذه السلوكيات؛ فسيقوم بمناقشة طرق علاج الأعراض أو الحد منها.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بالنسبة للآثار الجانبية ذات العلامة* لايمكن توفير تقييم دقيق لمعدل تكرارها؛ إذا إن هذه الآثار الجانبية لم تلاحظ في الدرسات السريرية التي تم إجراؤها على 2762 مريضا تم علاجهم ببراميبيكسول. على الأرجح أن فئة معدل التكرار لا تتجاوز تلك &quot;غير الشائعة&quot;.</p><p dir="RTL"><em>إذا كنت تعاني من متلازمة تململ الساقين، فقد تتعرض للآثار الجانبية التالية:</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدا:</strong></p><p dir="RTL">-غثيان (إعياء).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في نمط النوم،مثل:عدم القدرة على النوم (الأرق) والنعاس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب (إرهاق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلام غير طبيعية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء (إعياء).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة ملحة للتصرف بطريقة غير معتادة*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب (مشاكل بالقلب قد تسبب ضيقا بالتنفس أو تورم الكاحل)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفراز غير مناسب للهرمون المضاد لادرار البول*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الحركة (على سبيل المثال:حركات غير طبيعية وغير منضبطة للأطراف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحراك(على سبيل المثال:زيادة&nbsp; الحركة والعجز عن البقاء ساكنا)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جنون الارتياب (على سبيل المثال:خوف مبالغ فية على الصحة)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوهام*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة (اضطراب بالذاكرة)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلاوس (رؤية أو سماع أو الشعور بأشياء لا وجود لها).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك/التباس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس مفرط أثناء النهار والنوم&nbsp; فجاة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السوائل، عادة في الساقين (وذمة طرفية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (على سبيل المثال: طفح جلدي،حكة، فرط الحساسية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تململ (الشعور بعدم ارتياح).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور البصر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن بما في ذلك فقدان الشهية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس (صعوبات في التنفس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فواق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي (عدوى بالرئتين)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز عن مقاومة الرغبة أو الدافع أو الإغراء لفعل ماقد يضرك أو يضر الآخرين،والذي قد يتضمن:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة قوية للعب للقمار بشكل مفرط بالرغم من أن له عواقب شخصية أو عائلية خطيرة.*</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير أو زيادة الرغبة الجنسية والسلوك الذي يثير قلقا كبيرا لك أو للآخرين،مثل: زيادة الدافع الجنسي.*</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بالتسوق أو الإنفاق المفرط غير المتحكم به*</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شراهة (تناول كميات كبيرة من الطعام خلال مدة قصيرة)أو نهما (تناول كمية من الطعام أكبر من المعدل الطبيعي وأكثر من المطلوب لإشباع جوعك)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هوسا (هياجا، شعورا بالابتهاج أو فرط الاستثارة)*</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهذيان (أنخفاض الوعي،ارتباكا/التباسا، فقدان الصلة بالواقع)*</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معرفة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد التوقف عن العلاج بعقار سيفرول أو خفض الجرعة: قد يحدث اكتئاب أو لامبالاة أو إرهاق أو تعرق أو ألم (تسمى بمتلازمة انسحاب ناهض الدوبامين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك إذا كنت تواجه أيا من هذه السلوكيات؛ فسيقوم بمناقشة طرق علاج الأعراض أو الحد منها.</strong></p><p dir="RTL">بالنسبة للآثارالجانبية ذات العلامة* لا يمكن توفير تقييم دقيق لمعدل تكرارها؛ إذاإن هذه الآثار الجانبية لم تلاحظ في الدراسات السريرية التي تم إجراؤها على 1395 مريضا تم علاجهم ببراميبيكسول. على الأرجح أن فئة معدل التكرار لا تتجاوز تلك &quot;غير الشائعة&quot;.</p><p dir="RTL"><strong>الإبلاغ عن الاثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية اثار جانبية، فتحدث إلى طبيبك أو الصيدلي الخاص بك. و يشمل ذلك أية آثار جانبية محتملة، غير المدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول ورؤية الأطفال.</p><p dir="RTL">لاتتناول عقار سيفرول بعد تاريخ انتهاء الصلاحية المدون على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لايحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يحفظ في العبوة الأصلية لحماية الأقراص من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي براميبكسول.</p><p dir="RTL">يحتوي كل قرص على 0.088 مجم،أو 0.18 مجم، أو 0.35 مجم أو 0.7 مجم، براميبكسول في هيئة 0.125 مجم، أو 0.25 مجم، أو 0.5 مجم أو 1 مجم، براميبكسول ثنائي الهيدروكلوريد أحادي الهيدرات، على التوالي.</p><p dir="RTL">المكونات الأخرى هي مانيتول، ونشا الذرة، وسيليكا غروية لا مائية، وبوفيدون ك 25 وستيرات الماغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار سيفرول 0.088 مجم عبارة عن أقراص بيضاء اللون ودائرية الشكل ومسطحة ومكتوب عليها رمز بشكل بارز وليس بها خط تقسيم.</p><p dir="RTL">&nbsp;عقار سيفرول 0.18 مجم و عقار سيفرول 0.35 مجم عبارة عن أقراص بيضاء اللون وبيضاء الشكل ومسطحة ومكتوب عليها رمز بشكل بارز. الأقراص بها خط تقسيم ويمكن تقسيمها إلى نصفين.</p><p dir="RTL">عقار سيفرول 0.7 مجم عبارة عن أقراص بيضاء اللون ودائرية الشكل ومسطحة ومكتوب عليها رمز بشكل بارز. الأقراص بها خط تقسيم ويمكن تقسيمها إلى نصفين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">جميع أقراص لديها رمز شركة بوهرنجر إنجيلهايم تنقش على جانب واحد والرموزP6 أو P7 أو P8 أو P9 على الجانب الآخر، تمثل قوة قرص 0.088 ملغ،0.18 ملغ، و 0.35 ملغ و 0.7 ملغ، على التوالي</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر عقار سيفرول بكل تركيزاته في شرائط مصنوعة من الألمونيوم تحتوي كل منها على 10 أقراص، في عبوات كرتون تحتوي على عدد 3 أو 10 شرائط (30 أو 100 قرص). قد لايتم تسويق جميع أحجام العبوات و التراكيز في الأسواق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">شركة بوهرينجر إنجيلهايم إنترناشونال المحدودة، دي-55216 إنجيلهايم إيه إم راين ألمانيا.</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">شركة بوهرينجر إنجيلهايم فارما المحدودة وشركاه، شراكة محدودة، دي-55216 إنجيلهايم إيه إم راين ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر موافقة على هذه النشرة كانت في فبراير 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SIFROL 0.088 mg tablets
Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate equivalent to 0.088 mg pramipexole.

SIFROL 0.18 mg tablets
Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate equivalent to 0.18 mg pramipexole.

SIFROL 0.35 mg tablets
Each tablet contains 0.5 mg pramipexole dihydrochloride monohydrate equivalent to 0.35 mg pramipexole.

SIFROL 0.7 mg tablets
Each tablet contains 1.0 mg pramipexole dihydrochloride monohydrate equivalent to 0.7 mg pramipexole.

Please note:
Pramipexole doses as published in the literature refer to the salt form.
Therefore, doses will be expressed in terms of both pramipexole base and pramipexole salt (in brackets).

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet

SIFROL 0.088 mg tablets
The tablets are white, flat, of round shape, and have a code embossed (one side with the code P6, and one side with the Boehringer Ingelheim company symbol).

SIFROL 0.18 mg tablets
The tablets are white, flat, of oval shape, scored on both sides, and have a code embossed (one side with the code P7, and one side with the Boehringer Ingelheim company symbol).
Tablets can be divided into equal halves.

SIFROL 0.35 mg tablets
The tablets are white, flat, of oval shape, scored on both sides, and have a code embossed (one side with the code P8, and one side with the Boehringer Ingelheim company symbol).
Tablets can be divided into equal halves.

SIFROL 0.7 mg tablets
The tablets are white, flat, of round shape, scored on both sides, and have a code embossed (one side with the code P9, and one side with the Boehringer Ingelheim company symbol).
Tablets can be divided into equal halves.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SIFROL is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson&rsquo;s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or &ldquo;on off&rdquo; fluctuations).</p><p>&nbsp;</p><p>SIFROL is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Posology</p><p><u>Parkinson&rsquo;s disease</u></p><p>&nbsp;</p><p>The daily dose is administered in equally divided doses 3 times a day.</p><p>&nbsp;</p><p><em><u>Initial treatment</u></em></p><p>Doses should be increased gradually from a starting dose of 0.264 mg of base (0.375 mg of salt) per day and then increased every 5-7 days. Providing patients do not experience intolerable undesirable effects, the dose should be titrated to achieve a maximal therapeutic effect.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p>Ascending dose schedule of SIFROL</p></td></tr><tr><td style="vertical-align:top"><p>Week</p></td><td style="vertical-align:top"><p>Dose</p><p>(mg of base)</p></td><td style="vertical-align:top"><p>Total Daily Dose (mg of base)</p></td><td style="vertical-align:top"><p>Dose</p><p>(mg of salt)</p></td><td style="vertical-align:top"><p>Total Daily Dose (mg of salt)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3 x 0.088</p></td><td style="vertical-align:top"><p>0.264</p></td><td style="vertical-align:top"><p>3 x 0.125</p></td><td style="vertical-align:top"><p>0.375</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3 x 0.18</p></td><td style="vertical-align:top"><p>0.54</p></td><td style="vertical-align:top"><p>3 x 0.25</p></td><td style="vertical-align:top"><p>0.75</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3 x 0.35</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>3 x 0.5</p></td><td style="vertical-align:top"><p>1.50</p></td></tr></tbody></table><p>&nbsp;</p><p>If a further dose increase is necessary the daily dose should be increased by 0.54 mg of base (0.75 mg of salt) at weekly intervals up to a maximum dose of 3.3 mg of base (4.5 mg of salt) per day.</p><p>However, it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg (of salt) per day (see section 4.8).</p><p>&nbsp;</p><p><em><u>Maintenance treatment</u></em></p><p>The individual dose of pramipexole should be in the range of 0.264 mg of base (0.375 mg of salt) to a maximum of 3.3 mg of base (4.5 mg of salt) per day. During dose escalation in pivotal studies, efficacy was observed starting at a daily dose of 1.1 mg of base (1.5 mg of salt). Further dose adjustments should be done based on the clinical response and the occurrence of adverse reactions. In clinical trials approximately 5% of patients were treated at doses below 1.1 mg of base (1.5 mg of salt). In advanced Parkinson&rsquo;s disease, pramipexole doses higher than 1.1 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended. It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with SIFROL, depending on reactions in individual patients (see section 4.5).</p><p>&nbsp;</p><p><em><u>Treatment discontinuation</u></em></p><p>Abrupt discontinuation of dopaminergic therapy can lead to the development of a neuroleptic malignant syndrome or a dopamine agonist withdrawal syndrome. Pramipexole should be tapered off at a rate of 0.54 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.54 mg of base (0.75 mg of salt). Thereafter the dose should be reduced by 0.264 mg of base (0.375 mg of salt) per day (see section 4.4). Dopamine agonist withdrawal syndrome could still appear while tapering and a temporary increase of the dose could be necessary before resuming tapering (see section 4.4).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The elimination of pramipexole is dependent on renal function. The following dose schedule is suggested for initiation of therapy:</p><p>&nbsp;</p><p>Patients with a creatinine clearance above 50 ml/min require no reduction in daily dose or dosing frequency.</p><p>&nbsp;</p><p>In patients with a creatinine clearance between 20 and 50 ml/min, the initial daily dose of SIFROL should be administered in two divided doses, starting at 0.088 mg of base (0.125 mg of salt) twice a day (0.176 mg of base/0.25 mg of salt daily). A maximum daily dose of 1.57 mg pramipexole base (2.25 mg of salt) should not be exceeded.</p><p>&nbsp;</p><p>In patients with a creatinine clearance less than 20 ml/min, the daily dose of SIFROL should be administered in a single dose, starting at 0.088 mg of base (0.125 mg of salt) daily. A maximum daily dose of 1.1 mg pramipexole base (1.5 mg of salt) should not be exceeded.</p><p>&nbsp;</p><p>If renal function declines during maintenance therapy the SIFROL daily dose should be reduced by the same percentage as the decline in creatinine clearance, i.e. if creatinine clearance declines by 30%, then the SIFROL daily dose should be reduced by 30%. The daily dose can be administered in two divided doses if creatinine clearance is between 20 and 50 ml/min and as a single daily dose if creatinine clearance is less than 20 ml/min.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Dose adjustment in patients with hepatic failure is probably not necessary, as approx. 90% of absorbed active substance is excreted through the kidneys. However, the potential influence of hepatic insufficiency on SIFROL pharmacokinetics has not been investigated.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of SIFROL in children below 18 years has not been established. There is no relevant use of SIFROL in the paediatric population for the indication of Parkinson&rsquo;s Disease.</p><p>&nbsp;</p><p><u>Restless Legs Syndrome</u></p><p>&nbsp;</p><p>The recommended starting dose of SIFROL is 0.088 mg of base (0.125 mg of salt) taken once daily 2-3 hours before bedtime. For patients requiring additional symptomatic relief, the dose may be increased every 4-7 days to a maximum of 0.54 mg of base (0.75 mg of salt) per day (as shown in the table below).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Dose Schedule of SIFROL</p></td></tr><tr><td style="vertical-align:top"><p>Titration Step</p></td><td style="vertical-align:top"><p>Once Daily Evening Dose (mg of base)</p></td><td style="vertical-align:top"><p>Once Daily Evening Dose (mg of salt)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.088</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p>2*</p></td><td style="vertical-align:top"><p>0.18</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p>3*</p></td><td style="vertical-align:top"><p>0.35</p></td><td style="vertical-align:top"><p>0.50</p></td></tr><tr><td style="vertical-align:top"><p>4*</p></td><td style="vertical-align:top"><p>0.54</p></td><td style="vertical-align:top"><p>0.75</p></td></tr></tbody></table><p>* if needed</p><p>&nbsp;</p><p>Patient&rsquo;s response should be evaluated after 3 months treatment and the need for treatment continuation should be reconsidered. If treatment is interrupted for more than a few days it should be re-initiated by dose titration carried out as above.</p><p>&nbsp;</p><p><em><u>Treatment discontinuation</u></em></p><p>Since the daily dose for the treatment of Restless Legs Syndrome will not exceed 0.54 mg of base (0.75 mg of salt) SIFROL can be discontinued without tapering off. In a 26 week placebo controlled trial, rebound of RLS symptoms (worsening of symptom severity as compared to baseline) was</p><p>&nbsp;</p><p>observed in 10% of patients (14 out of 135) after abrupt discontinuation of treatment. This effect was found to be similar across all doses.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The elimination of pramipexole is dependent on renal function. Patients with a creatinine clearance above 20 ml/min require no reduction in daily dose.</p><p>The use of SIFROL has not been studied in haemodialysis patients, or in patients with severe renal impairment.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Dose adjustment in patients with hepatic failure is not required, as approx. 90% of absorbed active substance is excreted through the kidneys.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>SIFROL is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy.</p><p>&nbsp;</p><p><u>Tourette Disorder</u></p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>SIFROL is not recommended for use in children and adolescents below 18 years since the efficacy and safety has not been established in this population. SIFROL should not be used in children or adolescents with Tourette Disorder because of a negative benefit-risk balance for this disorder (see section 5.1).</p><p>&nbsp;</p><p>Method of administration</p><p><strong>&nbsp;</strong></p><p>The tablets should be taken orally, swallowed with water, and can be taken either with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When prescribing SIFROL in a patient with Parkinson&rsquo;s disease with renal impairment a reduced dose is suggested in line with section 4.2.</p><p>&nbsp;</p><p><u>Hallucinations</u></p><p>Hallucinations are known as a side effect of treatment with dopamine agonists and levodopa. Patients should be informed that (mostly visual) hallucinations can occur.</p><p>&nbsp;</p><p><u>Dyskinesia</u></p><p>In advanced Parkinson&rsquo;s disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of SIFROL. If they occur, the dose of levodopa should be decreased.</p><p>&nbsp;</p><p><u>Dystonia</u></p><p>Axial dystonia including antecollis, camptocormia and pleurothotonus (Pisa Syndrome) has occasionally been reported in patients with Parkinson&rsquo;s disease following initiation or incremental dose increase of pramipexole. Although dystonia may be a symptom of Parkinson&rsquo;s disease, the symptoms in these patients have improved after reduction or withdrawal of pramipexole. If dystonia occurs, the dopaminergic medication regimen should be reviewed and an adjustment in the dose of pramipexole considered.</p><p>&nbsp;</p><p><u>Sudden onset of sleep and somnolence</u></p><p>Pramipexole has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson&rsquo;s disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported uncommonly. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with SIFROL. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Furthermore a reduction of the dose or termination of therapy may be considered. Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see sections 4.5, 4.7 and section 4.8).</p><p>&nbsp;</p><p><u>Impulse control disorders</u></p><p>Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including SIFROL. Dose reduction/tapered discontinuation should be considered if such symptoms develop.</p><p>&nbsp;</p><p><u>Mania and delirium</u></p><p>Patients should be regularly monitored for the development of mania and delirium. Patients and carers should be made aware that mania and delirium can occur in patients treated with pramipexole. Dose reduction/tapered discontinuation should be considered if such symptoms develop.</p><p>&nbsp;</p><p><u>Patients with psychotic disorders</u></p><p>Patients with psychotic disorders should only be treated with dopamine agonists if the potential benefits outweigh the risks. Co-administration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.5).</p><p>&nbsp;</p><p><u>Ophthalmologic monitoring</u></p><p>Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.</p><p>&nbsp;</p><p><u>Severe cardiovascular disease</u></p><p>In case of severe cardiovascular disease, care should be taken. It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of postural hypotension associated with dopaminergic therapy.</p><p>&nbsp;</p><p><u>Neuroleptic malignant syndrome</u></p><p>Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2).</p><p>&nbsp;</p><p><u>Dopamine agonist withdrawal syndrome (DAWS)</u></p><p>DAWS has been reported with dopamine agonists, including pramipexole (see section 4.8). To discontinue treatment in patients with Parkinson&rsquo;s disease, pramipexole should be tapered off (see section 4.2). Limited data suggests that patients with impulse control disorders and those receiving high daily dose and/or high cumulative doses of dopamine agonists may be at higher risk for developing DAWS. Withdrawal symptoms may include apathy, anxiety, depression, fatigue, sweating and pain and do not respond to levodopa. Prior to tapering off and discontinuing pramipexole, patients should be informed about potential withdrawal symptoms. Patients should be closely monitored during tapering and discontinuation. In case of severe and/or persistent withdrawal symptoms, temporary re- administration of pramipexole at the lowest effective dose may be considered.</p><p>&nbsp;</p><p><u>Augmentation</u></p><p>Reports in the literature indicate that treatment of Restless Legs Syndrome with dopaminergic medicinal products can result in augmentation. Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities. Augmentation was specifically investigated in a controlled clinical trial over 26 weeks.</p><p>Augmentation was observed in 11.8% of patients in the pramipexole group (N = 152) and 9.4% of</p><p>&nbsp;</p><p>patients in the placebo group (N = 149). Kaplan-Meier analysis of time to augmentation showed no significant difference between pramipexole and placebo groups.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Plasma protein binding</u></p><p>Pramipexole is bound to plasma proteins to a very low (&lt; 20%) extent, and little biotransformation is seen in man. Therefore, interactions with other medicinal products affecting plasma protein binding or elimination by biotransformation are unlikely. As anticholinergics are mainly eliminated by biotransformation, the potential for an interaction is limited, although an interaction with anticholinergics has not been investigated. There is no pharmacokinetic interaction with selegiline and levodopa.</p><p>&nbsp;</p><p><u>Inhibitors/competitors of active renal elimination pathway</u></p><p>Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly with SIFROL.</p><p>&nbsp;</p><p><u>Combination with levodopa</u></p><p>When SIFROL is given in combination with levodopa, it is recommended that the dose of levodopa is reduced and the dose of other anti-parkinsonian medicinal products is kept constant while increasing the dose of SIFROL.</p><p>&nbsp;</p><p>Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see sections 4.4, 4.7 and 4.8).</p><p>&nbsp;</p><p><u>Antipsychotic medicinal products</u></p><p>Co-administration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.4), e.g. if antagonistic effects can be expected.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The effect on pregnancy and lactation has not been investigated in humans. Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at maternotoxic doses (see section 5.3). SIFROL should not be used during pregnancy unless clearly necessary, i.e. if the potential benefit justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>As pramipexole treatment inhibits secretion of prolactin in humans, inhibition of lactation is expected. The excretion of pramipexole into breast milk has not been studied in women. In rats, the concentration of active substance-related radioactivity was higher in breast milk than in plasma.</p><p>In the absence of human data, SIFROL should not be used during breast-feeding. However, if its use is unavoidable, breast-feeding should be discontinued.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No studies on the effect on human fertility have been conducted. In animal studies, pramipexole affected oestrous cycles and reduced female fertility as expected for a dopamine agonist. However, these studies did not indicate direct or indirect harmful effects with respect to male fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SIFROL can have a major influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Hallucinations or somnolence can occur.</p><p>&nbsp;</p><p>Patients being treated with SIFROL and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see also sections 4.4, 4.5 and 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on the analysis of pooled placebo-controlled trials, comprising a total of 1,923 patients on pramipexole and 1,354 patients on placebo, adverse drug reactions were frequently reported for both groups. 63% of patients on pramipexole and 52% of patients on placebo reported at least one adverse drug reaction.</p><p>&nbsp;</p><p>The majority of adverse drug reactions usually start early in therapy and most tend to disappear even as therapy is continued.</p><p>&nbsp;</p><p>Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><u>Parkinson&rsquo;s disease, most common adverse reactions</u></p><p>The most commonly (&ge; 5%) reported adverse drug reactions in patients with Parkinson&rsquo;s disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue. The incidence of somnolence is increased at doses higher than 1.5 mg pramipexole salt per day (see section 4.2). A more frequent adverse drug reaction in combination with levodopa was dyskinesia. Hypotension may occur at the beginning of treatment, especially if pramipexole is titrated too fast.</p><p>&nbsp;</p><p>Table 1: Parkinson&rsquo;s disease</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge;1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare (&ge;1/10,000</strong></p><p><strong>to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and</p><p>infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pneumonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>inappropriate antidiuretic</p><p>hormone secretion<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia hallucinations abnormal dreams confusion</p><p>&nbsp;</p><p>behavioural symptoms of impulse control disorders and compulsions</p></td><td style="vertical-align:top"><p>compulsive shopping pathological gambling restlessness hypersexuality delusion</p><p>libido disorder paranoia delirium&nbsp; binge eating<sup>1</sup></p><p>hyperphagia<sup>1</sup></p></td><td style="vertical-align:top"><p>mania</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>somnolence dizziness dyskinesia</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>sudden onset of sleep</p><p>amnesia hyperkinesia</p><p>syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>visual impairment including diplopia vision blurred</p><p>visual acuity reduced</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cardiac failure<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea hiccups</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>disorders</p></td><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>constipation</p><p>vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity pruritus</p><p>rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fatigue peripheral oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dopamine agonist withdrawal syndrome including apathy, anxiety, depression, fatigue,</p><p>sweating and pain.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>weight decrease including decreased</p><p>appetite</p></td><td style="vertical-align:top"><p>weight increase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1 This side effect has been observed in post-marketing experience. With 95 % certainty, the</p><p>frequency category is not greater than uncommon, but might be lower. A precise frequency estimation is not possible as the side effect did not occur in a clinical trial database of 2,762 patients with Parkinson&rsquo;s Disease treated with pramipexole.</p><p>&nbsp;</p><p><u>Restless Legs Syndrome, most common adverse reactions</u></p><p>The most commonly (&ge; 5%) reported adverse drug reactions in patients with Restless Legs Syndrome treated with pramipexole were nausea, headache, dizziness and fatigue. Nausea and fatigue were more often reported in female patients treated with SIFROL (20.8% and 10.5%, respectively) compared to males (6.7% and 7.3%, respectively).</p><p>&nbsp;</p><p>Table 2: Restless Legs Syndrome</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge;1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pneumonia<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>inappropriate antidiuretic hormone secretion<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>insomnia abnormal dreams</p></td><td style="vertical-align:top"><p>restlessness confusion hallucinations libido disorder delusion<sup>1</sup> hyperphagia<sup>1</sup> paranoia<sup>1</sup> mania<sup>1</sup> delirium<sup>1</sup></p><p>behavioural symptoms of impulse control disorders and compulsions<sup>1</sup> (such as:</p><p>compulsive shopping,</p><p>pathological gambling, hypersexuality, binge eating)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>headache dizziness somnolance</p></td><td style="vertical-align:top"><p>sudden onset of sleep syncope</p><p>dyskinesia amnesia<sup>1</sup> hyperkinesia<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>visual impairment including visual acuity reduced diplopia</p><p>vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cardiac failure<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dyspnoea hiccups</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p></td><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>constipation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity pruritus rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>peripheral oedema</p></td><td style="vertical-align:top"><p>Dopamine agonist withdrawal syndrome including apathy, anxiety, depression, fatigue, sweating and</p><p>pain</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>weight decrease including decreased appetite</p><p>weight increase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1 This side effect has been observed in post-marketing experience. With 95 % certainty, the</p><p>frequency category is not greater than uncommon, but might be lower. A precise frequency estimation is not possible as the side effect did not occur in a clinical trial database of 1,395 patients with Restless Legs Syndrome treated with pramipexole</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><u>Somnolence</u></p><p>Pramipexole is commonly associated with somnolence and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes (see also section 4.4).</p><p>&nbsp;</p><p><u>Libido disorders</u></p><p>Pramipexole may uncommonly be associated with libido disorders (increased or decreased).</p><p>&nbsp;</p><p><u>Impulse control disorders</u></p><p>Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including SIFROL (see section 4.4).</p><p>&nbsp;</p><p>In a cross-sectional, retrospective screening and case-control study including 3,090 Parkinson&rsquo;s disease patients, 13.6% of all patients receiving dopaminergic or non-dopaminergic treatment had symptoms of an impulse control disorder during the past six months. Manifestations observed include pathological gambling, compulsive shopping, binge eating, and compulsive sexual behaviour (hypersexuality). Possible independent risk factors for impulse control disorders included dopaminergic treatments and higher doses of dopaminergic treatment, younger age ( &le; 65 years), not being married and self-reported family history of gambling behaviours.</p><p>&nbsp;</p><p><u>Dopamine agonist withdrawal syndrome</u></p><p>Non-motor adverse effects may occur when tapering or discontinuing dopamine agonists including pramipexole. Symptoms include apathy, anxiety, depression, fatigue, sweating and pain (see section 4.4).</p><p>&nbsp;</p><p><u>Cardiac failure</u></p><p>In clinical studies and post-marketing experience cardiac failure has been reported in patients with pramipexole. In a pharmacoepidemiological study pramipexole use was associated with an increased risk of cardiac failure compared with non-use of pramipexole (observed risk ratio 1.86; 95% CI, 1.21- 2.85).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience with massive overdose. The expected adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension. There is no established antidote for overdose of a dopamine agonist. If signs of central nervous system stimulation are present, a neuroleptic agent may be indicated. Management of the overdose may require general supportive measures, along with gastric lavage, intravenous fluids, administration of activated charcoal and electrocardiogram monitoring.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: anti-Parkinson drugs, dopamine agonists, ATC code: N04BC05. <u>Mechanism of action</u></p><p>Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the D2 subfamily</p><p>of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity.</p><p>&nbsp;</p><p>Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover.</p><p>&nbsp;</p><p>The mechanism of action of pramipexole as treatment for Restless Legs Syndrome is unknown. Neuropharmacological evidence suggests primary dopaminergic system involvement.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>In human volunteers, a dose-dependent decrease in prolactin was observed. In a clinical trial with healthy volunteers, where SIFROL prolonged-release tablets were titrated faster (every 3 days) than recommended up to 3.15 mg pramipexole base (4.5 mg of salt) per day, an increase in blood pressure and heart rate was observed. Such effect was not observed in patient studies.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in Parkinson&rsquo;s disease</u></p><p>In patients pramipexole alleviates signs and symptoms of idiopathic Parkinson&rsquo;s disease. Placebo- controlled clinical trials included approximately 1,800 patients of Hoehn and Yahr stages I &ndash; V treated with pramipexole. Out of these, approximately 1,000 were in more advanced stages, received concomitant levodopa therapy, and suffered from motor complications.</p><p>&nbsp;</p><p>In early and advanced Parkinson&rsquo;s disease, efficacy of pramipexole in controlled clinical trials was maintained for approximately six months. In open continuation trials lasting for more than three years there were no signs of decreasing efficacy.</p><p>&nbsp;</p><p>In a controlled double blind clinical trial of 2 year duration, initial treatment with pramipexole significantly delayed the onset of motor complications, and reduced their occurrence compared to initial treatment with levodopa. This delay in motor complications with pramipexole should be balanced against a greater improvement in motor function with levodopa (as measured by the mean change in UPDRS-score). The overall incidence of hallucinations and somnolence was generally higher in the escalation phase with the pramipexole group. However, there was no significant</p><p>&nbsp;</p><p>difference during the maintenance phase. These points should be considered when initiating pramipexole treatment in patients with Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with SIFROL in all subsets of the paediatric population in Parkinson&rsquo;s Disease (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in Restless Legs Syndrome</u></p><p>The efficacy of pramipexole was evaluated in four placebo-controlled clinical trials in approximately 1,000 patients with moderate to very severe idiopathic Restless Legs Syndrome.</p><p>&nbsp;</p><p>The mean change from baseline in the Restless Legs Syndrome Rating Scale (IRLS) and the Clinical Global Impression-Improvement (CGI-I) were the primary efficacy outcome measures. For both primary endpoints statistically significant differences have been observed for the pramipexole dose groups 0.25 mg, 0.5 mg and 0.75 mg pramipexole salt in comparison to placebo. After 12 weeks of treatment the baseline IRLS score improved from 23.5 to 14.1 points for placebo and from 23.4 to 9.4 points for pramipexole (doses combined). The adjusted mean difference was -4.3 points (CI 95% -6.4;</p><p>-2.1 points, p-value &lt;0.0001). CGI-I responder rates (improved, very much improved) were 51.2% and 72.0% for placebo and pramipexole, respectively (difference 20% CI 95%: 8.1%; 31.8%, p&lt;0.0005). Efficacy was observed with 0.088 mg of base (0.125 mg of salt) per day after the first week of treatment.</p><p>&nbsp;</p><p>In a placebo-controlled polysomnography study over 3 weeks SIFROL significantly reduced the number of periodic limb movements during time in bed.</p><p>&nbsp;</p><p>Longer term efficacy was evaluated in a placebo-controlled clinical trial. After 26 weeks of treatment, there was an adjusted mean reduction in IRLS total score of 13.7 and 11.1 points in the pramipexole and placebo group, respectively, with a statistically significant (p = 0.008) mean treatment difference of -2.6. CGI-I responder rates (much improved, very much improved) were 50.3% (80/159) and 68.5% (111/162) for placebo and pramipexole, respectively (p = 0.001), corresponding to a number needed to treat (NNT) of 6 patients (95%CI: 3.5, 13.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with SIFROL in one or more subsets of the paediatric population in Restless Legs Syndrome (see section</p><p>4.2 for information on paediatric use).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in Tourette Disorder</u></p><p>The efficacy of pramipexole (0.0625-0.5 mg/day) with paediatric patients aged 6-17 years with Tourette Disorder was evaluated in a 6-week, double-blind, randomised, placebo-controlled flexible dose study. A total of 63 patients were randomised (43 on pramipexole, 20 on placebo). The primary endpoint was change from baseline on the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS). No difference was observed for pramipexole as compared to placebo for either the primary endpoint or for any of the secondary efficacy endpoints including YGTSS total score, Patient Global Impression of Improvement (PGI-I), Clinical Global Impression of Improvement (CGI-I), or Clinical Global Impressions of Severity of Illness (CGI-S). Adverse events occurring in at least 5% of patients in the pramipexole group and more common in the pramipexole-treated patients than in patients on placebo were: headache (27.9%, placebo 25.0%), somnolence (7.0%, placebo 5.0%),</p><p>nausea (18.6%, placebo 10.0%), vomiting (11.6%, placebo 0.0%), upper abdominal pain (7.0%,</p><p>placebo 5.0%), orthostatic hypotension (9.3%, placebo 5.0%), myalgia (9.3%, placebo 5.0%), sleep</p><p>disorder (7.0%, placebo 0.0%), dyspnoea (7.0%, placebo 0.0%) and upper respiratory tract infection (7.0%, placebo 5.0%). Other significant adverse events leading to discontinuation of study medication for patients receiving pramipexole were confusional state, speech disorder and aggravated condition (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Pramipexole is rapidly and completely absorbed following oral administration. The absolute bioavailability is greater than 90% and the maximum plasma concentrations occur between 1 and 3 hours. Concomitant administration with food did not reduce the extent of pramipexole absorption, but the rate of absorption was reduced. Pramipexole shows linear kinetics and a small inter-patient variation of plasma levels.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>In humans, the protein binding of pramipexole is very low (&lt; 20%) and the volume of distribution is large (400 l). High brain tissue concentrations were observed in the rat (approx. 8-fold compared to plasma).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Pramipexole is metabolised in man only to a small extent.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Renal excretion of unchanged pramipexole is the major route of elimination. Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces. The total clearance of pramipexole is approximately 500 ml/min and the renal clearance is approximately</p><p>400 ml/min. The elimination half-life (t&frac12;) varies from 8 hours in the young to 12 hours in the elderly.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated dose toxicity studies showed that pramipexole exerted functional effects, mainly involving the CNS and female reproductive system, and probably resulting from an exaggerated pharmacodynamic effect of pramipexole.</p><p>&nbsp;</p><p>Decreases in diastolic and systolic pressure and heart rate were noted in the minipig, and a tendency to a hypotensive effect was discerned in the monkey.</p><p>&nbsp;</p><p>The potential effects of pramipexole on reproductive function have been investigated in rats and rabbits. Pramipexole was not teratogenic in rats and rabbits but was embryotoxic in the rat at maternally toxic doses. Due to the selection of animal species and the limited parameters investigated, the adverse effects of pramipexole on pregnancy and male fertility have not been fully elucidated.</p><p>&nbsp;</p><p>A delay in sexual development (i.e., preputial separation and vaginal opening) was observed in rats. The relevance for humans is unknown.</p><p>&nbsp;</p><p>Pramipexole was not genotoxic. In a carcinogenicity study, male rats developed Leydig cell hyperplasia and adenomas, explained by the prolactin-inhibiting effect of pramipexole. This finding is not clinically relevant to man. The same study also showed that, at doses of 2 mg/kg (of salt) and higher, pramipexole was associated with retinal degeneration in albino rats. The latter finding was not observed in pigmented rats, nor in a 2-year albino mouse carcinogenicity study or in any other species investigated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol Maize starch</p><p>Anhydrous colloidal silica Povidone K 25 Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OPA/aluminium/PVC-aluminium blisters. Each blister strip contains 10 tablets.</p><p>Cartons containing 3 or 10 blister strips (30 or 100 tablets). Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boehringer Ingelheim International GmbH Binger Strasse 173
D-55216 Ingelheim am Rhein Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>